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The smooth muscle cells (SMC) of the aortic
wall play a central role in pathogenic processes that
commonly involve the distal aorta: atherosclerosis
and aneurysm. Both abnormal SMC proliferation
and alterations in matrix metabolism are involved in
these diseases.1-3 These abnormalities are mediated
in part by cytokines and growth factors elaborated
by infiltrating inflammatory cells and neighboring
endothelial cells.4 Cytokines and growth factors
exert their effects by interacting with specific recep-
tors on the surface of target cells. This receptor
interaction initiates a cascade of biochemical reac-
tions that eventually reaches the nucleus and alters
nuclear transcription. By using such complex intra-
cellular signaling mechanisms, a given cytokine or
growth factor can induce highly specific effects on
cellular function. 
To understand and selectively regulate the pro-
tean effects of cytokines and growth factors on aor-
tic SMC function, the relationship between individ-
ual intracellular signaling mechanisms and specific
cellular processes must be defined. Considerable
work has been directed toward this effort. The pro-
tein kinase C (PKC) signal transduction pathway has
been implicated in many fundamental vascular SMC
functions, including cell proliferation and differenti-
ation,5-7 response to mitogens,8 DNA synthesis,9
and gene expression.10,11 In addition, this cell sig-
naling mechanism is believed to be involved in the
regulation of matrix through its effects on matrix
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metalloproteinase expression, a process considered
central to the pathogenesis of abdominal aortic
aneurysm (AAA).12,13 There is strong evidence that
individual PKC isoforms, or unique combinations of
isoforms, mediate these diverse functions. The
potential for highly selective regulation of defined
cellular processes mediated through specific PKC
isoforms has prompted considerable interest in more
clearly characterizing the PKC enzymology of the
human aortic SMC.
The PKC family consists of at least 11 distinct
isoforms that maintain a remarkable structural
homology but differ in their enzymatic properties
and requirements for activation. The various PKC
subtypes can be classified into three groups consist-
ing of the classic, calcium and lipid dependent
forms, ( a , b I, b II, and g PKC), the novel calcium
independent/lipid dependent forms, (d , e , h , q , and
m PKC), and the atypical calcium independent/lipid
independent forms (z and l PKC).14 The classic and
novel isoforms are stimulated endogenously by the
lipid activator, 1,2-diacyl glycerol (DAG). Tumor
promoting phorbol esters such as 12-O-tetrade-
canoyl phorbol 13-acetate (TPA) can replace DAG
in activating these isoforms and have been used
extensively to characterize the role of these isoforms
in a variety of cellular processes.15,16
PKC isoform expression is tissue and cell type
specific with a given cell type expressing a character-
istic combination of several different isoforms. Indi-
vidual isoforms associate with anchoring proteins at
specific subcellular sites and translocate to other sites
when appropriately activated.17 This stimulated
translocation to another cellular compartment pre-
sumably represents a mechanism promoting access
to the isoform’s specific substrate, and thus provides
insight into the function performed by the individ-
ual isoforms. A number of molecular and pharmaco-
logic techniques are now being used to more direct-
ly demonstrate the unique function of specific iso-
forms.18-20 The logical extension of this technology
is the therapeutic blockade of specific PKC isoforms
mediating pathologic functions. Such therapeutic
intervention has yielded promising early results in a
rat model.21
These exciting developments have obvious impli-
cations for the treatment of vascular disease but
require a detailed understanding of the characteris-
tics of the particular PKC isoforms in human vascu-
lar SMC. To date, much of this work has been per-
formed in animal models and has yielded some con-
flicting results. To clarify our understanding of this
important cell signaling mechanism in vascular dis-
ease, we sought to identify the specific PKC isoforms
expressed in human arterial smooth muscle cells and
to define their subcellular location, as well as their
translocation with TPA activation.
METHODS
Arterial smooth muscle cell culture. Human
aortic tissue without gross or histologic evidence of
atherosclerosis was obtained during organ procure-
ment in accordance with a protocol approved by the
Institutional Review Board and Research Commit-
tee of the University of Nebraska Medical Center.
Cultures of SMC from the tunica media were estab-
lished by using previously described techniques.22
Briefly, the aortic media was separated from its
adventitia and intima, then minced and enzymatical-
ly digested to individual SMC. The liberated cells
were collected by filtration and centrifugation, and
then resuspended in serum-free M199 culture media
(Sigma, St. Louis, Mo.) and plated at 20,000 cells
per milliliter in 100 mm plates. Two hours later,
when the cells had attached, fetal bovine serum
(FBS) (Gibco, Grand Island, N.Y.) was added to a
final concentration of 10%. The SMC were then
grown to confluence and passaged by trypsinization.
Smooth muscle cell identity was verified by
immunohistochemical staining for a -actin (Enzo,
New York, N.Y.).
Identification of PKC isoforms by immunoblot
analysis. Early passage (p 2-4) cultured aortic SMC
were trypsinized, washed, and ultrasonically lysed in a
detergent buffer (buffer B) containing 20 mM
Tris/HCl pH7.5, 2 mM EDTA, 2 mM EGTA, 2 mM
DTT, 25 µg/ml aprotinin, 10 ug/ml leupeptin, 1
mM PMSF, 10% glycerol, 1.0% triton. (All reagents
from Sigma, St. Louis, Mo.) Cell lysates were incubat-
ed for 30 minutes on ice, solubilizing cytosolic and
membrane-bound PKC, which were then collected in
the supernatant after centrifugation at 20,000 · g for
20 minutes at 4° C. The protein concentration of this
cell lysate was determined by Bicinchoninic Acid assay
(Sigma, St. Louis), and an equal amount of protein
(160 m g) from each lysate was separated by SDS-
PAGE, (Biorad, Hercules, Calif.) then transferred to a
nitrocellulose membrane. Membranes were blocked
for 1 hour in 5% milk in buffer A containing 20 mM
Tris/HCl pH 7.5, 2 mM EDTA, 2 mM EGTA, 2 mM
DTT, 25 µg/ml aprotinin, 10 µg/ml leupeptin, 1
mM PMSF, 10% glycerol. (All reagents from Sigma,
St. Louis.) Blocked membranes were incubated at
room temperature for 1 hour with polyclonal anti-
bodies to the PKC isoforms a , b I, b II, d , e , g , and z
(Santa Cruz Biotechnology, Santa Cruz, Calif. ) dilut-
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ed 1:100 in buffer A. Preabsorption of the antibodies
with specific blocking peptides (Santa Cruz Biotech-
nology, Santa Cruz, Calif.) diluted 1:100 in buffer A
for 2 hours at 4° C was used to confirm the specificity
of each of the PKC isoform antibodies. Bands were
detected with enhanced chemiluminescence (Amer-
sham, Burlington Heights, Ill.) captured on X-OMAT
film (Kodak, Rochester, N.Y.).
Localization of PKC isoforms by immunoblot
analysis. To determine the general subcellular loca-
tion of each of the PKC isoforms before and after TPA
stimulation, early passage (p 2-4) cultured aortic SMC
were treated with 100 nM TPA (Sigma, St. Louis) in
M199 with 10% FBS for 30 minutes at 37° C in a
humidified 5% CO2 chamber. Control SMC were incu-
bated similarly in M199 with 10% FBS. Treated and
control SMC were washed twice in cold phosphate
buffered saline (PBS) and then mechanically lysed in
buffer A. This cell lysate was centrifuged at 20,000 · g
for 20 minutes at 4° C and the PKC from the soluble
cytosolic fraction was collected in the supernatant. PKC
bound to membrane or cytoskeletal elements remained
in the particulate fraction and was released in buffer B.
Protein normalized immunoblots as previously
described were performed, hybridizing the blocked
membranes for 1 hour with the same antibodies to the
PKC isoforms previously described. Bands were visual-
ized by enhanced chemiluminescence (Amersham,
Burlington Heights, Ill.) and quantitative analysis was
performed with the public domain NIH Image pro-
gram developed at the U.S. National Institute of
Health. Each experiment was performed in triplicate
with the proportion of each isoform in the soluble or
particulate fraction expressed as the mean ± SEM.
Translocation was defined as a significant change (P <
0.05) in the mean proportion of isoform in the partic-
ulate fraction of TPA-treated SMC compared with
untreated controls as determined by Student’s t test.
Specific blocking peptides were used as negative con-
trols as described in the previous section.
Localization of PKC isoforms by immunoflu-
orescent microscopy. To visualize the specific loca-
tion of each PKC isoform before and after TPA stim-
ulation, trypsinized early passage SMC (p 2-4) were
dispersed on glass chamber slides (Nunc, Inc.,
Naperville, Ill.) at a density of 40 K/cm2 in M199
with 10% FBS. After 24 hours, one chamber of each
slide was treated with 100 nM TPA in M199 with
10% FBS and the other chamber was left untreated.
The slides were then incubated at 37° C in a humid-
ified 5% CO2 chamber for 30 minutes. The media
was then removed and the cells washed twice with
cold PBS, fixed in ice cold methanol and acetone
(1:1) for 3 minutes, then washed again in cold PBS.
The fixed cells were incubated for 1 hour at room
temperature in 5% milk with 0.1% Triton X-100 fol-
lowed by hybridization with antibodies to the PKC
isoforms detected by immunoblot (a , b -I, b -II, d ,
and e ) diluted 1:50 in PBS containing 0.1% Triton
and 2 mg/ml bovine serum albumin. Cells were
next washed three times in PBS and incubated with
rhodamine conjugated antirabbit IgG antibody
(Boehringer, Mannheim, Germany) diluted 1:100 in
PBS for 1 hour in the dark. Cells were washed twice
with PBS and a coverslip was applied to each cham-
ber. A nonspecific antibody to rabbit IgG (Santa
Cruz Biotechnology, Santa Cruz, Calif.) diluted
1:100 in PBS containing 0.1% triton and 2 mg/ml
BSA was used as a negative control. Antibody stain-
ing was visualized with a Nikon Microphot-FXA
microscope (Nikon, Inc., Melville, N.Y.) and a Zeiss
confocal immunofluorescent microscope (Carl
Zeiss, Inc., Thornwood, N.Y.). Digital images were
processed using Adobe Photoshop 3.0 software
(Adobe Systems Inc., Mountain View, Calif.).
RESULTS
By immunoblot analysis of cell lysates, five of the
seven isoforms tested ( a , b I, b II, d , and e ) were
detected in human aortic SMC, whereas two of the
isoforms, g and z , were not detected (Fig. 1). Speci-
ficity of the antibodies used was confirmed by the
disappearance of bands when the antibodies were
preabsorbed with specific blocking peptides. Further
immunoblot analysis of the soluble and particulate
fractions of TPA-treated SMC and untreated con-
trols show that before TPA stimulation, the a iso-
form is detected primarily in the soluble fraction, but
after TPA stimulation, it translocates to the particu-
late fraction. Likewise, the proportion of b I isoform
detected in the particulate fraction of SMC increased
with TPA stimulation, consistent with translocation
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Fig. 1. Immunoblot detection of PKC isoforms in
human aortic SMC. Lysates of SMC were analyzed by
immunoblot with indicated PKC isoform antibodies. a ,
b I, b II, d , and e PKC isoforms were detected. Isoforms g
and z were not detected. Immunoblots were performed in
absence (-) or presence (+) of specific blocking peptides to
confirm specificity of antibodies used.
in response to this activator (Fig. 2). The isoforms
b II, d , and e were detected primarily in the particu-
late fraction in the resting state with no significant
change in response to TPA (Fig. 3).
Immunofluorescent microscopy and confocal
immunofluorescent microscopy of TPA-treated and
untreated SMC more clearly defined the location 
and stimulated translocation of these PKC isoforms
(Fig. 4). In unstimulated SMC, a PKC stained coarse-
ly throughout the cytosol with greater intensity in the
perinuclear area but with no staining visible within the
nucleus itself. With TPA stimulation, the a isoform
stained brightly within the nucleus and the cytosolic
immunoreactivity was sharply decreased. PKC b I
immunoreactivity also demonstrated a markedly differ-
ent pattern with TPA stimulation. In control SMC,
this isoform showed patchy cytosolic staining with per-
inuclear intensity but no intranuclear staining. With
TPA stimulation, b I immunoreactivity was detected
within the nucleus and also in association with the
plasma membrane. These immunofluorescent findings
illustrate the translocation of a and b I PKC from the
soluble to the particulate fraction demonstrated by
immunoblot analysis. In contrast to PKC a and b I, the
b II and d isoforms stained brightly in the perinuclear
regions and the e isoform localized to the nucleus,
with no detectable change after TPA stimulation.
These staining patterns corroborate the immunoblot
results detecting all three isoforms in the particulate
fraction in the resting state with no translocation on
TPA stimulation. Preabsorption of the antibodies with
specific blocking peptides eliminated the staining pat-
tern, and no staining was visualized with the nonspe-
cific rabbit IgG, confirming specificity of the antibod-
ies used. (Results not shown.)
DISCUSSION
Protein kinase C is increasingly recognized as a
key regulatory enzyme in vascular physiology. We
have identified five PKC isoforms present in human
aortic SMC. Two of these isoforms, a and b I,
responded to TPA stimulation by translocation from
the cytosol to the nuclear or the plasma membrane
as demonstrated by immunoblot analysis of cell frac-
tions and by immunohistochemistry. The b II, d , and
e isoforms localized to perinuclear and nuclear
regions and did not translocate in response to TPA
stimulation. The g and z isoforms were not detected
in these SMC. The fact that the isoforms detected
occupy specific locations and respond differently to
stimulation suggest that they perform unique func-
tions in cellular regulation.
Considerable progress has been made in defining
the unique functions of individual PKC isoforms in
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Fig. 2. PKC isoforms a and b I translocate from soluble
to particulate fraction in response to TPA. SMC were
treated or untreated (CON) with 100 nM TPA for 30
minutes. Cells were lysed and soluble (S) and particulate
(P) fractions collected and analyzed by immunoblot by
using antibodies to a and b I PKC. Each fraction was ana-
lyzed densitometrically with results expressed as percent-
age of isoform in each fraction. Translocation was defined
as significant change in percentage of isoform in particu-
late fraction from control cells compared with TPA-treat-
ed cells. Immunoblot and respective graph are shown.
Error bars denote SEM of triplicate experiments. Stu-
dent’s t test was used to compare mean percentage of par-
ticulate isoform from control and TPA group with P <
0.05 considered significant.
Fig. 3. PKC isoforms b II, d , and e are associated with par-
ticulate fraction and do not translocate in response to
TPA. SMC were treated or untreated (CON ) with 100
nM TPA for 30 minutes. Cells were lysed and soluble (S)
and particulate (P) fractions collected and analyzed by
immunoblot with antibodies to PKC b II, d , and e . Each
fraction was analyzed densitometrically and results
expressed as percentage of isoform in each fraction.
Immunoblot and respective graph are shown. Error bars
denote SEM of triplicate analyses.
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Fig. 4. Localization of PKC isoforms in human aortic SMC. SMC were treated or untreated
(CON) with 100 nM TPA for 30 minutes, then stained with antibodies to PKC a , b I, b II, d ,
and e isoforms. TPA treatment changed cellular localization of a and b I isoforms compared
with control, whereas b II, d , and e staining was similar in both control and TPA treated cells.
Primary antibody staining was visualized with secondary antibody conjugated to rhodamine by
indirect immunofluorescence (original magnification, · 200).
complex signal transduction pathways. Such funda-
mental vascular SMC functions as proliferation and
differentiation have been linked to specific PKC iso-
forms. Sasaguri et al.6 showed that the isoforms a
and e are involved in inhibition of mitotic progres-
sion from G1 to S phase, whereas Fukumoto et al.23
demonstrated that PKC d inhibits SMC proliferation
by suppressing G1 cyclin expression. Haller et al.5
showed that a -actin expression, a marker of SMC
differentiation, is increased when PKC a is up regu-
lated and that PKC a is down regulated in rapidly
proliferating SMC. A number of important vascular
SMC agonists have also been linked to the activation
of specific PKC isoforms. Haller et al.8 demonstrat-
ed that angiotensin II induced the translocation of a
PKC from the cytosol to both the nucleus and to
cytoskeletal elements, whereas PDGF induced
translocation of this isoform only to the nuclear
region. In the same model, both agonists induced
translocation of the b isoform from the cytosol to
perinuclear and nuclear regions More recently,
Haller et al.24 have demonstrated that high glucose
concentrations induce the translocation of a , b , and
e into the nucleus, whereas d showed strong associ-
ation with cytoskeletal structures. Taken together,
these data suggest that individual PKC isoforms, or
unique combinations of isoforms, mediate agonist
specific functions by translocating to specific cellular
compartments. The site of isoform translocation
provides an important clue to the biologic function
of that isoform; translocation to cytoskeletal ele-
ments suggests the regulation of contractile or mor-
phologic functions while translocation to the nucle-
us suggests the regulation of gene expression or
mitotic events. 
Linking individual isoforms with specific biolog-
ic functions provides an opportunity to selectively
manipulate the PKC signal transduction system for
therapeutic benefit. Given the central role PKC plays
in normal physiologic cell function, it is important
that any manipulation of this system be specifically
targeted to particular isoforms mediating defined
pathologic processes. A number of molecular and
pharmacologic techniques have been developed to
allow such selective regulation. By using recombi-
nant gene technology, Nagpala et al.20 induced the
selective overexpression of b I PKC in human
microvascular endothelial cells. These cells showed
increased phorbol ester-induced endothelial perme-
ability thus linking a particular isoform to a defined
biologic function and providing a mode for selective
regulation of that function. Other groups have used
isoform specific antisense oligonucleotide therapy to
selectively suppress individual isoforms, with promis-
ing early results.18,25 Ron et al.26 mapped part of the
PKC anchoring protein binding site on b PKC and
used those sequences to selectively block transloca-
tion of this isoform. Importantly, the selective block-
ing of this isoform was associated with significantly
inhibited b I PKC mediated biologic activity in a
Xenopus oocyte model. These technologies are
rapidly being translated from cell models to animal
models and hold considerable promise as a mode of
therapeutic intervention. Synthetic isoform-specific
PKC inhibitors have been particularly useful in this
regard. Ishii et al.21 treated diabetic rats orally with
a synthetic oral inhibitor of b PKC and demonstrat-
ed improved glomerular filtration rate, albumin
excretion rate, and retinal circulation in a dose
responsive manner and in parallel to its inhibition of
PKC activities.
Much of our understanding of the PKC signal
transduction mechanism in vascular SMC has been
developed from animal models. As we begin to trans-
late this animal work into clinical interventions in
human disease, it becomes critical to define PKC
enzymology in human cells. The organization of this
complex signal transduction mechanism is certainly
tissue specific and may be species specific as well.
Haller et al.24 detected the isoforms a , b I, b II, d , and
e , as well as z in unstimulated rat aortic SMC. In this
model, e PKC localized to the cytosol, whereas we
detected this isoform primarily in the nucleus in
human aortic SMC. Although several other authors
have detected z -PKC in rat or ferret aortic SMC,27-29
we did not detect this isoform in our human cells. 
Studies performed in human aortic SMC have
generally been limited, and the results somewhat
inconsistent. Liao et al.27 detected the z isoform in
neonatal human aortic SMC, whereas our SMC, pro-
cured from an exclusively adult population, did not
show detectable z expression. Erdbrugger et al.30
analyzed rat and human aortic tissue homogenates
that were partially purified by phenylsepharose col-
umn chromatography and detected the z isoform in
both. The partial purification process significantly
augments detection of rare isoforms, which, in this
case, may actually be produced by cells other than
SMC in the tissue homogenate. Finally, although we
consistently detected b PKC by both immunoblot
analysis and immunohistochemistry, other investiga-
tors failed to detect this isoform in human and rat
aortic SMC.27,29 This discrepancy may be due to
degradation during the processing of their speci-
mens. Other sources of inconsistency between these
various studies may relate to the culture conditions
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used. It is well-recognized that cultured vascular
SMC undergo gradual phenotypic changes with pas-
sage.31 More specifically, PKC isoform expression
can vary with increasing passage.5 We used a narrow
range of early passage cells (p 2-4) to control that
source of variability. The presence or absence of
serum may also be a confounding factor. We chose to
conduct our experiments in cells grown to conflu-
ence in the presence of serum as this condition mim-
ics the in vivo situation. Others have rendered their
cultured SMC quiescent by serum deprivation for 48
hours before experimentation.29 Disatnik et al.32
investigated the effect of serum deprivation on PKC
isoforms in cultured cardiac myocytes and found sub-
tle differences in the localization of some of the iso-
forms, but in none did serum determine the presence
or absence of a given isoform.
CONCLUSION
The PKC signal transduction system is broadly
involved in many important vascular SMC functions.
We are particularly interested in its role in cytokine
mediated regulation of matrix metalloproteinase
expression, a process central to the development of
AAA. Cytokines use specific PKC isoforms, or com-
binations of these isoforms, to signal unique biolog-
ic effects. Relating specific PKC isoform activation
with particular biologic effects provides an opportu-
nity to regulate those effects in a highly selective
manner. To this end, we have identified five PKC
isoforms in human aortic SMC and defined their
subcellular location and response to TPA stimula-
tion. The translocation of the a and b I isoforms with
TPA treatment is of particular interest as TPA is
known to stimulate production of matrix metallo-
proteinases in vascular SMC. We hope to extend
these findings by more directly linking stimulated
aortic SMC metalloproteinase production with spe-
cific PKC isoform activation with the long-term goal
of selectively blocking those particular isoforms and
inhibiting matrix degradation in aortic aneurysms.
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Dr. Jeffrey Alexander (Cleveland, Ohio). There are a
number of intracellular signalling proteins, protein kinase
C being one of them, and it has become clear that each
one involves a dynamic and seemingly endless array of pro-
tein interactions that occur in different spacial and tempo-
ral patterns. Protein kinase C presents an additional set of
variables in that this enzyme now has 11 identified iso-
forms. Each subspecies appears to have unique properties
that include its expression, intracellular location, and
requirements for activation. It is not surprising that their
individual effects on cell function may also be quite differ-
ent. In 1983, Croft and Anderson first reported that after
its activation, protein kinase C translocates from a soluble
site of plasmic compartment to a particulate fraction of the
cell that has subsequently been shown to include plasma
membrane, endoplasmic reticulum, mitochondria, and
even cytoskeletal material.
The direction and effect of this translocation may
vary according to the isoform and the location of its
receptor protein. For example, protein kinase C epsilon
has been shown to translocate in some smooth muscle
cell species to the cytoskeletal fraction where it plays a
role in contractility. Other isoforms have also been
shown to be essential, or at least an important compo-
nent, of cell replication. In this study of human smooth
muscle cells, protein kinase C alpha and beta I isoforms
were found to translocate from the soluble to the partic-
ulate fraction of the cell in response to phorbol stimula-
tion, and beta II, delta, and epsilon remained within the
particulate fraction. The gamma and zeta isozymes that
have been found in other species of vascular tissues were
not detected here.
Other investigators have demonstrated that isozyme
expression can be altered by the phenotypic state of the
cell, that is, whether it is secretory or contractile, resting
or stimulated, or even growing in a culture plate versus
growing in tissue. The cells studied here were maintained
in 10% fetal bovine serum, which might lead to earlier
activation and translocation of some of these isoforms.
Can we be sure that this has not already caused a translo-
cation of beta II, delta, and epsilon to the particulate frac-
tion before tetradecanoyl phorbol acetate stimulation, and
would it not have been better to use a basal maintenance
medium instead?
In the same context, cells undergoing immunofluo-
rescent staining were applied to a cover slip at a relatively
low population density and were likely to be in a state of
active replication when studied. Might this have influ-
enced the pattern of translocation to the nucleus as
shown with immunofluorescent staining as compared
with quiescent cells or with cells subjected to a single
external stimulus?
My second concern regarding the methodology and
conclusions that might be drawn from this study is that
although there are several main activators of protein kinase
C isoforms, it is not very clear what promotes the atypical
isoform, such as zeta, which did not have specific phorbol
binding sites. Therefore, if it is not identified in this par-
ticular setting, can it be assumed not to exist in the human
smooth muscle cell?
The patterns of cellular protein activation are transient
and complex and are very important for our understand-
ing and our potential control of pathologic processes such
as intimal hyperplasia, atherosclerosis, and aneurysm for-
mation. The authors of this fascinating and well-prepared
manuscript are to be complimented for their efforts to
unravel this confusing maze of intracellular signaling.
Thank you.
Dr. Janet J. Grange. Dr. Alexander, thank you for
your insightful comments and questions. I will certainly
try to address those issues. Regarding how these experi-
ments were designed, obviously we are getting into some
very complex intracellular mechanisms that we are trying
to demonstrate in a cell culture model. Clearly, in cell cul-
ture models, there are variables that are impossible to
duplicate from in vivo, namely the phenotype of the cells
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DISCUSSION
with which you are working. So, I think that any results
from a cell culture model will have to be interpreted in
that light.
We debated about whether to perform these experi-
ments in the presence or absence of serum. We decided to
use serum primarily because these PKC isoforms are in the
presence of serum proteins in vivo, and we elected to con-
trol for that by exposing both our control cells and our
treated cells to serum. However, your comment about
translocation of the delta, beta I, and epsilon isoforms
because of that serum is certainly valid. We feel that those
isoforms are also seen in serum in vivo, so this may be an
inappropriate way to study them in vitro.
As I mentioned, the replication stage of any cell model
is important in determining what kinds of proteins the cell
expresses at a given moment in time. A fairly nice mono-
layer actually is created on our glass slides by 40,000 cells
per cm2. We felt the experiments were performed on them
quickly after they attached, so we attempted to catch the
cells at a moment in time when they were just attached.
Again, any results obtained from cell culture models must
obviously be interpreted in the light of the replicated stage
in which they are found.
I would like to close with the observation that we are
in the initial stages of studying a very complex system.
There are many different variables that are difficult to con-
trol, but I think each step made is a small step in under-
standing this very complicated system. This is with the
hopes of eventually being able to regulate some intracellu-
lar processes that are pathologic. Thank you again.
JOURNAL OF VASCULAR SURGERY
Volume 27, Number 5 Grange et al. 927
